Exploring Fenofibrate Formulations for the Treatment of Lipid Disorders: Past, Present, and Future
Author:
Affiliation:
1. College of Pharmacy, Chungnam National University, Daejeon, Korea.
Funder
National Research Foundation of Korea
Publisher
Korean Society of CardioMetabolic Syndrome
Subject
Organic Chemistry,Biochemistry
Link
https://e-cmsj.org/pdf/10.51789/cmsj.2022.2.e13
Reference106 articles.
1. Hyperlipidemia as a Risk Factor for Cardiovascular Disease
2. Triglycerides and cardiovascular disease
3. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort
4. High-Density Lipoprotein and Cardiovascular Risk
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. In-situ sequential crystallization of fenofibrate and tristearin – Understanding the distribution of API in particles and stability of solid lipid microparticles from the perspective of crystallization;European Journal of Pharmaceutics and Biopharmaceutics;2024-09
2. Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome;Diseases;2023-10-13
3. Profound Modification of Fatty Acid Profile and Endocannabinoid-Related Mediators in PPARα Agonist Fenofibrate-Treated Mice;International Journal of Molecular Sciences;2022-12-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3